endTB aims to find shorter, less toxic and more effective treatments for ‘multidrug-resistant TB’ (MDR-TB) through:

  • access to new drugs
  • two clinical trials
  • advocacy at national and global levels.

Covering 18 countries, the project is a partnership between Partners In Health, Médecins Sans Frontières, Interactive Research & Development and financial partners UNITAID and the Transformational Investment Capacity (TIC) of MSF. 

Watch the two-minute animation


You can contact us, or follow us on Twitter.

endTB trial data analysis now underway

Medecins sans Frontieres (MSF) Counsellor Sagar Kumar Patra accompanying the patient to endTB clinic in Aundh Chest Hospital, Pune, India.

July 10, 2023

Médecins Sans Frontières/Doctors Without Borders (MSF), Partners In Health (PIH) and Interactive Research and Development (IRD), with funding from global health agency Unitaid are happy to announce that analysis of the endTB trial data is now underway.

The endTB trial was started to address the problem of multidrug-resistant TB (MDR-TB) treatments, which were long, ineffective and have terrible side effects. The study was performed to identify radically shorter (nine months), more tolerable and injection-free treatments for MDR-TB.

Read more


endTB clinical trial partners announce completion of the Last Patient Last Visit

endTB participant and Dra Jimena Ruiz, Hospital Nacional Sergio Bernales, Lima, Peru

April 11, 2023

The endTB clinical trial, funded by global health agency Unitaid, has reached another milestone. The endTB consortium partners, Médecins Sans Frontières/Doctors Without BordersPartners In Health and Interactive Research and Development are pleased to share that the last visit for the last study participant in the endTB trial was completed on 8 April.

The endTB consortium will now advance to the final stages of analyzing the study results. This trial is a critical step towards advancing viable, shorter, and more effective treatments for all patients with multidrug- or rifampin-resistant (MDR/RR) TB, including children, pregnant people, people living with important comorbidities such as HIV, hepatitis C, diabetes mellitus, and substance-use disorder. 

Read more 


PIH MSF MSF UNITAID Médecins Sans Frontières (MSF) Transformational Investment Capacity (TIC) logo